Yellow Fever - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Yellow Fever - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Yellow Fever - Pipeline Review, H2 2014', provides an overview of the Yellow Fever's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Yellow Fever
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Yellow Fever and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Yellow Fever pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Yellow Fever
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Yellow Fever Overview 6
Therapeutics Development 7
Pipeline Products for Yellow Fever - Overview 7
Pipeline Products for Yellow Fever - Comparative Analysis 8
Yellow Fever - Therapeutics under Development by Companies 9
Yellow Fever - Therapeutics under Investigation by Universities/Institutes 10
Yellow Fever - Pipeline Products Glance 11
Early Stage Products 11
Yellow Fever - Products under Development by Companies 12
Yellow Fever - Products under Investigation by Universities/Institutes 13
Yellow Fever - Companies Involved in Therapeutics Development 14
Panacea Biotec Limited 14
Janssen Pharmaceuticals, Inc. 15
NewLink Genetics Corporation 16
iBio, Inc. 17
Arbovax, Inc. 18
Themis Bioscience GmbH 19
Yellow Fever - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Molecule Type 25
Drug Profiles 27
yellow fever vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
yellow fever vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
yellow fever vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
yellow fever vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Flaviviruses Infection Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LCTA-949 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DiTU - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BG-323 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
yellow fever vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
yellow fever vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
yellow fever [YF-17D] (polyvalent) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Yellow Fever - Recent Pipeline Updates 38
Yellow Fever - Dormant Projects 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products under Development for Yellow Fever, H2 2014 7
Number of Products under Development for Yellow Fever - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Yellow Fever - Pipeline by Panacea Biotec Limited, H2 2014 14
Yellow Fever - Pipeline by Janssen Pharmaceuticals, Inc., H2 2014 15
Yellow Fever - Pipeline by NewLink Genetics Corporation, H2 2014 16
Yellow Fever - Pipeline by iBio, Inc., H2 2014 17
Yellow Fever - Pipeline by Arbovax, Inc., H2 2014 18
Yellow Fever - Pipeline by Themis Bioscience GmbH, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Yellow Fever Therapeutics - Recent Pipeline Updates, H2 2014 38
Yellow Fever - Dormant Projects, H2 2014 39